Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Apr 20;14:1148021. doi: 10.3389/fphar.2023.1148021

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 Jian, Zhan, Yu, Yu, Hu, Wang and Lu.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Comparison of therapies for improving OS in patients with high-volume disease. (A) Forest plot representing HR for combination therapy compared with ADT with or without SNA. (B) Forest plot representing HR for specific therapy compared with ADT with or without SNA. (C) SUCRA plot showing the treatment ranking of specific therapies. (D) League table of NMA comparing the OS. Comparison is located at the intersection of the column-defining treatment and the row-defining treatment. The results are presented in HR with 95% CrI. HR > 1 (red) favors row-defining treatment, and HR < 1 (green) favors column-defining treatment. The dark red or green represents the results with statistical significance. DOC, Docetaxel; ABI, Abiraterone, ENZA, Enzalutamide; APA, Apalutamide; REZ, Rezvilutamide; OS, overall survival; ADT, androgen deprivation therapy; SNA, standard non-steroidal antiandrogen; HR, hazard ratio; NMA, network meta-analysis; SUCRA, surface under the cumulative ranking curve.